The FDA wants pro-life states to keep waiting

For 26 years, the U.S. Food and Drug Administration has delayed safety reviews for the dangerous chemical abortion drug mifepristone and defied every attempt to subject the drug to normal medical scrutiny. Still, the FDA claims, as it recently told the 5th Circuit during oral arguments in Louisiana v. FDA, pro-life states such as Louisiana […]

≈